Lilly and China's NCCD announce collaboration to advance scientific understanding and care for people living with diabetes and cardiovascular disease
As a response to this national epidemic, the collaboration will:
- Evaluate the health economic consequences of diabetes in
- Develop a simple cardiovascular disease (CVD) risk calculator to improve screening and diabetes management at the primary care level.
- Analyze patient samples to identify new biomarkers for diabetes progression, diabetic kidney diseases (DKD), and CVD.
- Develop and distribute medical education for health care professionals treating diabetes related CVD in
To learn more about how these goals will be achieved, watch this video.
"As the number of people living with diabetes continues to grow rapidly throughout
By 2045, the number of people living with diabetes is expected to rise to 629 million worldwide, with type 2 diabetes being the most common form, accounting for around 90 percent of all cases.[ii] Due to complications associated with diabetes, CVD is a major complication and the leading cause of death associated with diabetes.[iii],[iv] Approximately 50 percent of deaths in people with type 2 diabetes worldwide are caused by CVD.[v],[vi]
The collaboration will leverage data collected by the Patient-centered Evaluative Assessment of
"We are grateful to the NCCD for their willingness to collaborate with us on initiatives that will advance our understanding of these complex diseases," said
An estimated 425 million adults worldwide have diabetes.[ii] Type 2 diabetes is the most common form, accounting for around 90 percent of all cases.[ii] Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin.
NCCD, set up as a national prevention platform for cardiovascular disease in 2009, aims to organize and carry out the national prevention and research. NCCD advocates more partners implementing the national prevention strategy. For more information, visit www.nccd.org.cn
About Lilly Diabetes
Lilly has been a global leader in diabetes care since 1923, when we introduced the world's first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.com.
Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com and http://newsroom.lilly.com/social-channels. P-LLY
i Wang L, Gao P, Zhang M, et al. Prevalence and ethnic pattern of diabetes and pre-diabetes in
v Nwaneri C, et al. Mortality in Type 2 Diabetes Mellitus: Magnitude of the Evidence from a Systematic Review and Meta-analysis.
vi Morrish NJ, et al. Mortality and Causes of Death in the WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia 2001;44(2):S14–21.
View original content with multimedia:http://www.prnewswire.com/news-releases/lilly-and-chinas-nccd-announce-collaboration-to-advance-scientific-understanding-and-care-for-people-living-with-diabetes-and-cardiovascular-disease-300635717.html